Laboratorios Farmaceuticos RoviLABFF 93 Debt-to-Equity is 0.17 as of Mar. 2026, which is 6% below its 10-year median of 0.18. GuruFocus rates LABFF with a GF Score™ of 93/100 and a GF Value™ of $82.42. The stock has 1 warning sign investors should review. Among 811 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks better than 62.52% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Debt-to-Equity or its related term are showing as below:
LABFF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.12 Med: 0.18 Max: 0.27
Current: 0.17
During the past 13 years, the highest Debt-to-Equity Ratio of Laboratorios Farmaceuticos Rovi was 0.27. The lowest was 0.12. And the median was 0.18.
LABFF's Debt-to-Equity is ranked better than 62.52% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs LABFF: 0.17
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Laboratorios Farmaceuticos Rovi Debt-to-Equity Related Terms
Laboratorios Farmaceuticos Rovi Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LABFF vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (LABFF) has a Debt-to-Equity of 0.17 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is near median its historical median of 0.18. Over the past decade, Laboratorios Farmaceuticos Rovi's Debt-to-Equity has ranged from 0.12 to 0.27. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #304 out of 811 companies in the Drug Manufacturers industry, placing it in the top 37.5%.
Is Laboratorios Farmaceuticos Rovi's Debt-to-Equity too high?
Laboratorios Farmaceuticos Rovi's current Debt-to-Equity of 0.17 is near median its 10-year median of 0.18. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 0.27. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Laboratorios Farmaceuticos Rovi's value of 0.17 is 37% below this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #304 out of 811 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #304 out of 811 companies for Debt-to-Equity. This puts Laboratorios Farmaceuticos Rovi in the upper half of its industry. The industry median Debt-to-Equity is 0.27. Laboratorios Farmaceuticos Rovi's value of 0.17 is 37% below this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own Debt-to-Equity has ranged from 0.12 to 0.27 over the past decade. While the company's 10-year median is 0.18 vs. the industry median of 0.27, Laboratorios Farmaceuticos Rovi has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Debt-to-Equity of 0.17 is 37% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Debt-to-Equity is 0.17, which is near median its own 10-year median of 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current Debt-to-Equity of 0.17. The stock's GF Value™ is $82.42, compared to a current price of $90.61 — trading 9.9% above its estimated fair value. The current Debt-to-Equity is 0.17, which is near median its 10-year median of 0.18 and 37% below the Drug Manufacturers industry median of 0.27. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Debt-to-Equity is 0.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of $90.61 is trading 9.9% above its estimated GF Value™ of $82.42.
Key valuation signals for LABFF:
Debt-to-Equity: 0.17 (near median its 10-year median of 0.18)
GF Value™: $82.42 vs. price of $90.61 (9.9% above fair value)
Industry Position: 37% below the Drug Manufacturers median (#304 of 811)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score
Get the complete analysis for LABFF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 
